Clinical Trial: Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease

U.S., June 16 -- ClinicalTrials.gov registry received information related to the study (NCT07646652) titled 'Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease' on June 08.

Brief Summary: The goal of the study is to assess if learning one's Lewy Body Dementia (LBD) biomarker test result impacts longitudinal psychosocial and behavioral responses and to identify factors that moderate and mediate these outcomes.

Study Start Date: Nov., 2026

Study Type: OBSERVATIONAL

Condition: Lewy Body Disease

Intervention: OTHER: LBD Biomarker Education and Disclosure

In-depth interviews as well as questionnaires will be conducted with individuals who have preclinical (early stage) or symptomati...